Augustin M, Krieger T, McBride D, Graham CN, Melzer N, Kneidl J, Neidhardt K. Cost-effectiveness of secukinumab as first biologic treatment for psoriasis compared with initiating other biologic therapy in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A568-9.
Halliday A, Hacking V, Jugl SM, Gunda P, Nikoglou E, Miles L, Graham CN. Budget impact of secukinumab for ankylosing spondylitis in the UK. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A535.
Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy. Clin Ther. 2016 Jun;38(6):1376-91. doi: 10.1016/j.clinthera.2016.03.023
Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling psoriatic arthritis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A233-4.
Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling ankylosing spondylitis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A234.
Graham CN, Miles L, McBride D, Zhao Y, Herrera V. Estimation of annual indirect costs associated with moderate-to-severe plaque psoriasis in the United States. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA.
Graham CN, Davis KL, Goyal RK. Effect of sample size and data maturity on parametric survival modeling projections in advanced cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Knoof A, Lanier J, Knox HN, Barber B, de Pouvourville G. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type ras metastatic colorectal cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016